Clinical and Translational Research Center, University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
NCT Number: NCT01605435
Frailty is a geriatric syndrome leading to physical deterioration including muscle wasting (sarcopenia) and unintentional weight loss. There are currently no approved therapies for frailty. Ghrelin is a hormone produced by the stomach that stimulates appetite centers in the brain. The purpose of this study is to determine the optimal subcutaneous ghrelin dose as a potential intervention for frail elderly individuals. We will examine food intake and metabolic parameters after placebo and ghrelin administration at three escalating subcutaneously administered doses.
Looking for future studies?
Notify Me70 year and older
All sexes
Interventional
Phase 2
Philadelphia, Pennsylvania, 19104, United States
This study is to determine the optimal ghrelin dose for use in a daily subcutaneous dosing study in frail individuals. Using data from our previous study and the published literature, we have designed a single blind, single dose administration study in which we will examine food intake after ghrelin administration and metabolic parameters (plasma glucose, insulin, free fatty acids, and cortisol) pre and post ghrelin administration.We have selected a dose range using our own and previously published studies from which we will determine subcutaneous doses to use in subsequent studies. The selection criteria for subsequent studies will be the dose that maximizes food intake by more than 30% without inducing hyperglycemia or raising cortisol levels. Participants must meet all inclusion criteria and have no exclusion criteria. Data will be analyzed after the first three participants have completed the protocol and used to inform dose modifications for the next three participants. Data from this portion of the study will be analyzed immediately after its completion, to allow updates to the design of the next study.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exhaustion: Two statements are read:
Exclusion criteria
-
The first two participants received placebo at baseline visit, 2 mcg/kg as a single subcutaneous dose at Visit 2, 5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4. There was 3-10 days between visits.
Other names: First dose escalation group
The next three participants received placebo at baseline visit, 5 mcg/kg as a single subcutaneous dose at Visit 2, 7.5 mcg/kg as a single subcutaneous dose at Visit 3, and 10 mcg/Kg as a single subcutaneous dose at visit 4.
Other names: Second dose escalation group
Time frame: 30 days following the last administration of study treatment.
Number and type of treatment emergent adverse events
Time frame: 30 mins post-ghrelin or placebo
Median energy intake at breakfast, which was served 30 minutes post-placebo or ghrelin administration demonstrated at each dose level.
Time frame: 30 mins post-ghrelin or placebo
% of total energy relative to placebo - breakfast served 30 minutes post-placebo or ghrelin administration.
Time frame: 30 minutes after ghrelin administration
median growth hormone peak 30 minutes after placebo/ghrelin.
Time frame: 0, 60 and 120 minutes after dosing
Cortisol response to ghrelin or placebo - levels at 0, 60 and 120 minutes after dosing
Time frame: 0 minutes (baseline) and 60 or 90 minutes from dosing
Median fasting and peak postprandial Glucose levels (60 or 90 minutes from dosing) at placebo and at each ghrelin dose.
Time frame: 0 and 90 minutes after dosing
Median fasting insulin levels at baseline and 90 minutes after dosing
Time frame: 90 and 120 minutes after dosing
Free Fatty Acid levels (mEq/L) at 60 and 90 minutes after meal (90 and 120 minutes)
University of Pennsylvania
Other
Ghrelin In Frail Elderly Subcutaneous Dose Finding Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.